HUMACYTE INC (HUMA) Stock Price & Overview
NASDAQ:HUMA • US44486Q1031
Current stock price
The current stock price of HUMA is 0.6424 USD. Today HUMA is up by 8.53%. In the past month the price decreased by -41.06%. In the past year, price decreased by -52.41%.
HUMA Key Statistics
- Market Cap
- 123.983M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.20
- Dividend Yield
- N/A
HUMA Stock Performance
HUMA Stock Chart
HUMA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to HUMA. When comparing the yearly performance of all stocks, HUMA is a bad performer in the overall market: 93.56% of all stocks are doing better.
HUMA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to HUMA. HUMA has a bad profitability rating. Also its financial health evaluation is rather negative.
HUMA Earnings
On March 27, 2026 HUMA reported an EPS of -0.13 and a revenue of 467.00K. The company beat EPS expectations (3.2% surprise) and missed revenue expectations (-65.91% surprise).
HUMA Forecast & Estimates
13 analysts have analysed HUMA and the average price target is 8.01 USD. This implies a price increase of 1147.55% is expected in the next year compared to the current price of 0.6424.
For the next year, analysts expect an EPS growth of -127.8% and a revenue growth 343.06% for HUMA
HUMA Groups
Sector & Classification
HUMA Financial Highlights
Over the last trailing twelve months HUMA reported a non-GAAP Earnings per Share(EPS) of -0.2. The EPS increased by 84.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.09% | ||
| ROE | -1313.38% | ||
| Debt/Equity | 20.08 |
HUMA Ownership
HUMA Latest News, Press Relases and Analysis
HUMA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About HUMA
Company Profile
Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company is headquartered in Durham, North Carolina and currently employs 218 full-time employees. The company went IPO on 2020-09-22. The firm is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The firm develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. The company is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The firm is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The firm is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.
Company Info
IPO: 2020-09-22
HUMACYTE INC
2525 East North Carolina Highway 54
Durham NORTH CAROLINA US
CEO: Rajiv Shukla
Employees: 218
Phone: 19193139633
HUMACYTE INC / HUMA FAQ
What does HUMA do?
Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company is headquartered in Durham, North Carolina and currently employs 218 full-time employees. The company went IPO on 2020-09-22. The firm is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The firm develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. The company is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The firm is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The firm is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.
What is the current price of HUMA stock?
The current stock price of HUMA is 0.6424 USD. The price increased by 8.53% in the last trading session.
Does HUMA stock pay dividends?
HUMA does not pay a dividend.
How is the ChartMill rating for HUMACYTE INC?
HUMA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for HUMACYTE INC?
HUMACYTE INC (HUMA) operates in the Health Care sector and the Biotechnology industry.
What is the Price/Earnings (PE) ratio of HUMACYTE INC (HUMA)?
HUMACYTE INC (HUMA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.2).
Should I buy HUMA stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on HUMA.